BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Vitner EB, Avraham R, Politi B, Melamed S, Israely T. Elevation in sphingolipid upon SARS-CoV-2 infection: possible implications for COVID-19 pathology. Life Sci Alliance 2022;5:e202101168. [PMID: 34764206 DOI: 10.26508/lsa.202101168] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Trivedi VS, Magnusen AF, Rani R, Marsili L, Slavotinek AM, Prows DR, Hopkin RJ, McKay MA, Pandey MK. Targeting the Complement-Sphingolipid System in COVID-19 and Gaucher Diseases: Evidence for a New Treatment Strategy. Int J Mol Sci 2022;23. [PMID: 36430817 DOI: 10.3390/ijms232214340] [Reference Citation Analysis]
2 Hu Q, Liu B, Fan Y, Zheng Y, Wen F, Yu U, Wang W. Multi-omics association analysis reveals interactions between the oropharyngeal microbiome and the metabolome in pediatric patients with influenza A virus pneumonia. Front Cell Infect Microbiol 2022;12. [DOI: 10.3389/fcimb.2022.1011254] [Reference Citation Analysis]
3 Hou J, Wei Y, Zou J, Jaffery R, Liang S, Zheng C, Chen K, Shi P, Chen Y, Xie X, Peng W. Integrated multi-omics analyses identify key anti-viral host factors and pathways controlling SARS-CoV-2 infection.. [DOI: 10.21203/rs.3.rs-1910932/v1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Smith CD, Maines LW, Keller SN, Katz Ben-yair V, Fathi R, Plasse TF, Levitt ML. Recent Progress in the Development of Opaganib for the Treatment of Covid-19. DDDT 2022;Volume 16:2199-2211. [DOI: 10.2147/dddt.s367612] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
5 Liu P, Hu D, Yuan L, Lian Z, Yao X, Zhu Z, Li X. Metabolomics Analysis of PK-15 Cells with Pseudorabies Virus Infection Based on UHPLC-QE-MS. Viruses 2022;14:1158. [PMID: 35746630 DOI: 10.3390/v14061158] [Reference Citation Analysis]
6 Oh K, Adnan M, Cho D. Network Pharmacology Study to Elucidate the Key Targets of Underlying Antihistamines against COVID-19. CIMB 2022;44:1597-609. [DOI: 10.3390/cimb44040109] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]